Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.31 |
| ▸ | AURKA | O14965 | 1/20 | 0.31 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.31 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.31 |
| ▸ | PAK4 | O96013 | 1/20 | 0.31 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
| ▸ | CSF1R | P07333 | 1/20 | 0.31 |
| ▸ | RET | P07949 | 1/20 | 0.31 |
| ▸ | MET | P08581 | 1/20 | 0.31 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.31 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.31 |
| ▸ | FLT1 | P17948 | 1/20 | 0.31 |
| ▸ | GRK5 | P34947 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | FLT3 | P36888 | 1/20 | 0.31 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.31 |
| ▸ | CLK2 | P49760 | 1/20 | 0.31 |
| ▸ | GSK3A | P49840 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22918490 | 0.69 | — | — | |
| SCHEMBL461170 | 0.63 | PIK3CA (0.31) | FGFR1RPS6KA3PRKXPRKCQTNK2 | |
| SCHEMBL10281635 | 0.61 | CCR1 (0.33) | — | |
| SCHEMBL5494546 | 0.60 | ABL1 (0.36) | AURKADAPK3MAP4K4ABL1RET | |
| SCHEMBL23679320 | 0.58 | GABRA5 (0.36) | — | |
| SCHEMBL24983651 | 0.57 | LMNA (0.30) | — | |
| SCHEMBL4071831 | 0.56 | RET (0.43) | CHEK1AURKADAPK3JAK2PRKD3 | |
| SCHEMBL5487082 | 0.56 | SMPD3 (0.38) | CHEK1AURKADAPK3MAP4K4ABL1 | |
| SCHEMBL997527 | 0.56 | PRMT5 (0.35) | — | |
| SCHEMBL4952993 | 0.56 | CHEK1 (0.31) | CHEK1AURKADAPK3JAK2PRKD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331729-A1 | 4-IMIDAZOPYRIDAZIN-1-YL-BENZAMIDES AS BTK INHIBITORS | MERCK SHARP & DOHME (NL) | 2023-10-19 | — | — | US | disclosed |
| EP-4249076-A2 | (S)-4-(8-AMINO-3-(1-(BUT-2-YNOYL)PYRROLIDIN-2-YL)IMIDAZO[1,5-A]PYRAZIN-1-YL)-2-METHOXY-N-(PYRIDIN-2-YL)BENZAMIDE AS BTK-INHIBITOR | Merck Sharp & Dohme B.V. (NL) | 2023-09-27 | — | — | EP | disclosed |
| EP-3495368-B1 | (S)-4-(8-AMINO-3-(1-(BUT-2-YNOYL)PYRROLIDIN-2-YL)IMIDAZO[1,5-A]PYRAZIN-1-YL)-2-METHOXY-N-(PYRIDIN-2-YL)BENZAMIDE AS BTK-INHIBITOR | MERCK SHARP & DOHME (NL) | 2023-05-31 | — | — | EP | disclosed |
| EP-3689878-B1 | 4-IMIDAZOPYRIDAZIN-1-YL-BENZAMIDES AND 4-IMIDAZOTRIAZIN-1-YL-BENZAMIDES AS BTK-INHIBITORS | MERCK SHARP & DOHME (NL) | 2021-10-06 | — | — | EP | disclosed |
| US-20210230166-A1 | 4-IMIDAZOPYRIDAZIN-1-YL-BENZAMIDES AS BTK INHIBITORS | MERCK SHARP & DOHME B.V. (NL) | 2021-07-29 | — | — | US | disclosed |
| US-10934296-B2 | 4-imidazopyridazin-1-yl-benzamides as Btk inhibitors | MERCK SHARP & DOHME B.V. (NL) | 2021-03-02 | — | — | US | disclosed |
| EP-3689878-A1 | 4-IMIDAZOPYRIDAZIN-1-YL-BENZAMIDES AND 4-IMIDAZOTRIAZIN-1-YL-BENZAMIDES AS BTK-INHIBITORS | Merck Sharp & Dohme B.V. (NL) | 2020-08-05 | — | — | EP | disclosed |
| US-20190276456-A1 | 4-IMIDAZOPYRIDAZIN-1-YL-BENZAMIDES AS BTK INHIBITORS | MERCK SHARP & DOHME B.V. (NL) | 2019-09-12 | — | — | US | disclosed |
| EP-3495368-A1 | (S)-4-(8-AMINO-3-(1-(BUT-2-YNOYL)PYRROLIDIN-2-YL)IMIDAZO[1,5-A]PYRAZIN-1-YL)-2-METHOXY-N-(PYRIDIN-2-YL)BENZAMIDE AS BTK-INHIBITOR | Merck Sharp & Dohme B.V. (NL) | 2019-06-12 | — | — | EP | disclosed |
| EP-2948458-B1 | BTK INHIBITORS | MERCK SHARP & DOHME (US) | 2019-05-01 | — | — | EP | disclosed |
| US-7534797-B2 | 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2009-05-19 | — | — | US | disclosed |
| US-7534797-B2 | 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2009-05-19 | — | — | US | disclosed |
| US-7534797-B2 | 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2009-05-19 | — | — | US | disclosed |
| US-20090118499-A1 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors | OSI PHARMACEUTICALS, INC. | 2009-05-07 | — | — | US | disclosed |
| US-20090118499-A1 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors | OSI PHARMACEUTICALS, INC. | 2009-05-07 | — | — | US | disclosed |
| US-20070149521-A1 | Bicyclic protein kinase inhibitors | OSI PHARMACEUTICALS, INC. | 2007-06-28 | — | — | US | disclosed |
| US-20070149521-A1 | Bicyclic protein kinase inhibitors | OSI PHARMACEUTICALS, INC. | 2007-06-28 | — | — | US | disclosed |
| US-20070149521-A1 | Bicyclic protein kinase inhibitors | OSI PHARMACEUTICALS, INC. | 2007-06-28 | — | — | US | disclosed |
| WO-2007064993-A2 | BICYCLIC PROTEIN KINASE INHIBITORS | OSI PHARMACEUTICALS, INC. (US) | 2007-06-07 | — | — | WO | disclosed |
| US-20060235031-A1 | 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors | ACERTA PHARMA B.V. (NL) | 2006-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118499-A1 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors | IGF1R, MAP2K7, BRCA1 | CHEK1 188/4885AURKA 1854/4885DAPK3 688/4885 |
| US-20070149521-A1 | Bicyclic protein kinase inhibitors | CDK1, MAP4K2, MAP4K3 | CHEK1 177/4885AURKA 422/4885DAPK3 205/4885 |
| US-10934296-B2 | 4-imidazopyridazin-1-yl-benzamides as Btk inhibitors | BTK, SYK, ABL1 | CHEK1 634/4885AURKA 417/4885DAPK3 367/4885 |
| US-20210230166-A1 | 4-IMIDAZOPYRIDAZIN-1-YL-BENZAMIDES AS BTK INHIBITORS | BTK, SYK, ABL1 | CHEK1 634/4885AURKA 417/4885DAPK3 367/4885 |
| US-20190276456-A1 | 4-IMIDAZOPYRIDAZIN-1-YL-BENZAMIDES AS BTK INHIBITORS | BTK, SYK, ABL1 | CHEK1 634/4885AURKA 417/4885DAPK3 367/4885 |
| US-20060235031-A1 | 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors | IGF1R, MAP2K7, BRCA1 | CHEK1 188/4885AURKA 1854/4885DAPK3 688/4885 |
| US-20230331729-A1 | 4-IMIDAZOPYRIDAZIN-1-YL-BENZAMIDES AS BTK INHIBITORS | BTK, SYK, ABL1 | CHEK1 634/4885AURKA 417/4885DAPK3 367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.